

# UCLA

## UCLA Previously Published Works

### Title

Glutamate and GABA Imbalance Following Traumatic Brain Injury

### Permalink

<https://escholarship.org/uc/item/4sd6d48z>

### Journal

Current Neurology and Neuroscience Reports, 15(5)

### ISSN

1528-4042

### Authors

Guerriero, Réjean M  
Giza, Christopher C  
Rotenberg, Alexander

### Publication Date

2015-05-01

### DOI

10.1007/s11910-015-0545-1

Peer reviewed



Published in final edited form as:

*Curr Neurol Neurosci Rep.* 2015 May ; 15(5): 27. doi:10.1007/s11910-015-0545-1.

## Glutamate and GABA imbalance following traumatic brain injury

Réjean M. Guerriero<sup>1,2,3</sup>, Christopher C. Giza<sup>4,5</sup>, and Alexander Rotenberg<sup>1,2,3</sup>

<sup>1</sup>Division Epilepsy, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA

<sup>2</sup>Brain Injury Center, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA

<sup>3</sup>Neuromodulation Program, Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA

<sup>4</sup>Division of Pediatric Neurology, Mattel Children's Hospital, UCLA Brain Injury Research Center, Los Angeles, CA

<sup>5</sup>Department of Neurosurgery and David Geffen School of Medicine at UCLA, Los Angeles, CA

### Abstract

Traumatic brain injury (TBI) leads to multiple short and long term changes in neuronal circuits that ultimately conclude with an imbalance of cortical excitation and inhibition. Changes in neurotransmitter concentrations, receptor populations and specific cell survival are important contributing factors. Many of these changes occur gradually, which may explain the vulnerability of the brain to multiple mild impacts, alterations in neuroplasticity, and delays in the presentation of post-traumatic epilepsy. In this review we provide an overview of normal glutamate and GABA homeostasis, and describe acute, subacute and chronic changes that follow injury. We conclude by highlighting opportunities for therapeutic interventions in this paradigm.

### Keywords

Post-traumatic epilepsy; Parvalbumin interneuron; glutamate transporter; NMDA receptor

### Introduction

Advances in translational neuroscience research, coupled with increased attention from the medical community, have provided valuable insight into the mechanisms by which traumatic brain injury (TBI) leads to posttraumatic neurologic symptoms such as motor and cognitive deficits and post-traumatic epilepsy. While posttraumatic pathophysiology remains

---

Corresponding Author: Réjean M. Guerriero, DO, Division of Epilepsy, Department of Neurology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, p617-355-2490; f781-216-2517, Rejean.guerriero@childrens.harvard.edu.

#### Addresses

Christopher C. Giza, MD, Room 18-218B Semel Institute, UCLA Brain Injury Research Center, Department of Neurosurgery, 10833 Le Conte Blvd, Los Angeles, CA 90095, cgiza@mednet.ucla.edu

Alexander Rotenberg, MD, PhD, Division of Epilepsy, Department of Neurology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115. alexander.rotenberg@childrens.harvard.edu

incompletely understood, much of the morbidity, particularly after moderate to severe TBI, may be referable to a pathologic shift toward excess excitability of the normal cortical excitation:inhibition ratio. Accordingly, the present review focuses on an overview of the major cortical excitation and inhibition mechanisms, and relevant pathologic changes that follow TBI in humans and in experimental models.

Glutamate is the primary excitatory neurotransmitter in the brain, while  $\gamma$ -aminobutyric acid (GABA) is the principal inhibitory neurotransmitter. The balance of glutamatergic and GABAergic tone is crucial to normal neurologic function. The role of glutamate signaling in TBI pathophysiology is twofold. On one hand, acute posttraumatic glutamate release is responsible for excitotoxicity following brain injury that leads to neuronal injury, cell death and dysfunction of surviving neurons; on the other hand, delayed disruption of excitatory glutamate circuits leads to deficits in cognitive and motor function, and in experience-dependent plasticity.

Pyramidal neurons, located in the cortex and hippocampus of mammals, as well as neurons of the midbrain, hypothalamus and cerebellum produce glutamate that is central to excitatory signaling pathways [1]. Alternatively, GABA is produced in interneurons that modulate cortical and thalamocortical circuits that relay sensory information and play a role in coordinating motor functions, attention, and memory [2,3].

GABA modulates excitatory pathways in the brain and, following injury, loss of GABA producing cells disrupts the balance of excitation and inhibition leading to further cell injury and apoptosis. The results of glutamate excitotoxicity share common elements from mild [4] to severe TBI, as well as status epilepticus, ischemia, and neurodegenerative diseases [5]. In addition to this imbalance in excitation and inhibition, traumatic neuronal injuries may lead to cell damage via mitochondrial dysfunction, axonal shearing, oxidative stress, and abnormalities in cerebral vasculature that are beyond the scope of this review.

In this review we discuss the effect of TBI on cortical glutamate and GABA balance, with particular focus on posttraumatic epilepsy (PTE) as it provides a clear, objective endpoint following TBI and has a number of well-characterized animal models. Severe TBI leads to PTE in approximately 20% of the civilian population after closed head injury and 50% in war veterans with penetrating head wounds [6–8]. It is the most frequent cause of acquired epilepsy in young adults [9]. Notably, PTE does not immediately follow TBI. Rather, PTE follows a latent period of epileptogenesis [10] that follows acute post-traumatic glutamate release [11–14] and leads to immediate and delayed neuronal death and dysfunction [15,16]. This latent period provides the ideal setting to investigate the cellular dysfunction and plasticity that follow TBI and is a unique opportunity to test neuroprotective or antiepileptogenic agents.

We begin with a review of normal glutamate and GABA signaling and homeostasis. We follow with the pathophysiology of TBI beginning acutely and then injury progression over time, including subacute changes in receptors and chronic changes in cellular networks. We conclude with opportunities for neuroprotective intervention.

## Normal Glutamate and GABA Balance

### Glutamate Homeostasis

Glutamate has been appreciated as important in metabolic brain processes for over 60 years [17]. Glutamate is synthesized from glutamine in presynaptic glutamatergic neurons. It is then stored in presynaptic vesicles. A depolarizing current prompts entry of calcium into the presynaptic cell via voltage-gated channels, triggering an intracellular calcium sensor that leads to vesicular release into the synaptic cleft [18]. Following release of glutamate and its action mainly on postsynaptic receptors, it is taken up by astrocytes, largely by excitatory amino acid transporter (EAAT2) in humans or glutamate transporter-1 (GLT-1) in rodents [19,20]. In astrocytes, glutamate is converted to glutamine by glutamine synthase and shuttled back to the presynaptic neuron [21] (see Figure, Panel A).

### Glutamate Receptors and Physiology

Glutamate acts on either ionotropic receptors enabling ion passage into the cell or metabotropic G-protein coupled receptors, both of which prompt an intracellular signaling cascade. The ionotropic receptors include N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and kainate. The NMDA receptor (NMDAR) has been the most extensively studied due to its role in use-dependent synaptic plasticity, particularly long-term potentiation [22], and its potential contribution to diseases such as schizophrenia and Alzheimer's Disease [2,23,24]. Of note, this review highlights observed receptor and subunit changes following TBI (see Table), and is not meant to be a comprehensive discussion of subunits and receptor physiology.

The NMDAR is a tetramer of combinations of its NR1, NR2 and NR3 subunits [25]. NR1, NR2A and NR2B subunits have received the most attention in TBI research. The NR1 subunit binds glycine, an inhibitory neurotransmitter, and is responsible for receptor deactivation [25]. NR2A-containing NMDARs are often colocalized with NR1, predominantly at the synapse, and activation of these receptors strengthens synapses and induces proplasticity signals, such as pErk, pCREB and BDNF [26,27]. Conversely, NR2B-containing NMDARs are localized extrasynaptically, and their activation results in signals more detrimental to the cell. Activation of NR2B results in prolonged calcium influx that appears to be more specifically taken up by mitochondria, leading to subsequent mitochondrial dysfunction and increased activity of caspases, all of which promote cell damage and demise [28–30]. Finally, NR2B containing neurons are more susceptible to mechanical injury versus NR2A neurons and a greater proportion of NR2B neurons leads to impaired neuronal connectivity and plasticity [31,32]. Shifts in these NMDAR subunits have important ontogenic and functional consequences. During normal circuit development, whether it be in brain *in vivo*, hippocampal slices or neuronal cell culture, immature NMDARs are predominantly NR2B-containing and, with maturation there is increasing expression of NR2A-containing NMDARs [33]. As we will see later TBI also influences the expression of these subunits.

Typically ionotropic receptors require binding of the neurotransmitter alone to open the ion channel. The NMDA channel, however, has the unique property of requiring binding of

glutamate, as well as post-synaptic membrane depolarization, often by neighboring AMPA channels, to prompt ion influx. It functions, in effect, as a coincidence detector, linking pre-synaptic and post-synaptic activation. At rest, the NMDAR's ion channel pore is blocked by a  $Mg^{++}$  ion, which is removed by post-synaptic depolarization, rendering it permeable to both  $Na^+$  and  $Ca^{++}$  [2]. This is essential for normal neurotransmission, but has implications for excitotoxicity following TBI. If excess glutamate is released then the cell membrane remains depolarized leading to increased  $Ca^{++}$  entry into the post-synaptic cell.

The AMPA receptor (AMPA) is also formed by a tetramer of subunits, including GluR1-4. The GluR1 and GluR2 subunits will be focused on here. The GluR1 subunit, located synaptically, makes the AMPAR permeable to  $Na^+$  and  $Ca^{++}$  and has been implicated in synaptic plasticity and learning and memory [34,35]. GluR1 is regulated by phosphorylation that may be driven by NMDAR binding, including activation of calcium/calmodulin-dependent protein kinases (CaMKs), specifically CaMKII. The selective activation of specific CaMKs is important for long term-potential and normal memory function; however, indiscriminate activation can lead to impairments [2,34,36]. The GluR2 subunit is also synaptic, however it makes the AMPAR impermeable to calcium [37], and thus is protective against the pro-apoptotic effects of increased  $Ca^{++}$ . Phosphorylation of GluR2 by protein kinase C (PKC) leads to endocytosis of the GluR2 subunit and impaired synaptic plasticity [38] (see Table).

### GABA Homeostasis

GABA is the primary inhibitory neurotransmitter of the central nervous system and its release from interneurons acts to modulate excitatory neurotransmission. Glutamine in astrocytes is transported to GABAergic neurons to be converted to glutamate and then immediately to GABA by glutamate decarboxylase (GAD). Glutamate, glutamine and GABA rely on intermediaries from the tricarboxylic acid (TCA) cycle; therefore deficits and inefficiencies in cellular energy metabolism, such as those that follow compromised tissue perfusion and increased neuronal metabolic demand after TBI, also lead to deficits in transmitter production [21]. GABA is stored in presynaptic vesicles and is released onto postsynaptic terminals that may be located on the dendritic projections, the cell body, axon, or another axon terminal [2]. Following release and its post-synaptic actions the majority of GABA is taken back up by its transporter, GAT-1 into the presynaptic neuron. It is then recycled back into presynaptic vesicles for subsequent release (see Figure, Panel A).

### GABA Receptors and Physiology

Following release, GABA acts on GABA-A and GABA-B receptors. GABA-A receptors are post-synaptic ionotropic receptors that cause the opening of  $Cl^-$  channels and lead to hyperpolarization of the postsynaptic cell. GABA-A receptors may be either synaptic or extrasynaptic. GABA-B receptors are metabotropic, G-protein coupled receptors that act via a second messenger cascade. GABA-B receptors may be post-synaptic or pre-synaptic and lead to the opening of  $K^+$  channels, which in the presynaptic terminal limits GABA release. Post-synaptically,  $K^+$  leads to even more pronounced hyperpolarization than  $Cl^-$ , lasting longer than the action of GABA-A receptors [2,21,39].

The GABA-A receptor contains at least 16 subunits. Different subtype combinations lead to different physiologic characteristics and pharmacologic profiles. The combination of these subtypes relies on co-localization on the neuronal membrane [40]. The GABA-A subunits that have received the most attention in TBI research are  $\alpha 1$ ,  $\gamma 2$ ,  $\alpha 4$  and  $\delta 1$ . These subunits contribute to GABA interneurons' ability to modulate neuronal signals via phasic and tonic inhibition. These two types of inhibition have unique functions. Phasic inhibition decreases the hyperexcitability of the post-synaptic cell and plays an important role in the creation and modulation of theta and gamma oscillations. Alternatively, tonic inhibition provides more constant maintenance of the amount and duration of the post-synaptic depolarization [41]. This inhibition may contribute to rhythmic oscillations that act to time and synchronize the excitatory impulses [2,42]. Phasic and tonic inhibition are dependent on the amount and speed of GABA release as well as the differential action of post-synaptic receptors. The GABA-A receptor subunits involved in phasic inhibition are  $\alpha 1$  and  $\gamma 2$ , while tonic inhibition involves  $\alpha 4$  and  $\delta 1$  subunits [43]. When GABA is released rapidly from presynaptic vesicles it diffuses quickly across the synaptic space and acts on  $\alpha 1$  and  $\gamma 2$  containing GABA-A receptors leading to phasic inhibition. Alternatively, lower concentrations of ambient or released GABA act on extrasynaptic receptors containing  $\alpha 4$  and  $\delta 1$  subunits. These lower, more constant concentrations lead to tonic inhibition [40,43] (see Table).

The phasic action of GABA inhibitory signals creates a network of competing rhythmic oscillations that aid in the timing and synchronization of neuronal signals. The parvalbumin positive, fast-spiking GABAergic interneurons, which approximate 40% of the total cortical GABAergic interneuron population, are key to this process [44]. This GABAergic interneuron subtype creates gamma frequency oscillations that are felt to enhance information processing through an improved signal to noise ratio [45]. Therefore, damage to specific receptor subtypes or cell populations may affect the modulation of cell signaling, leading to abnormal synchronization and decreased inhibitory tone that render the cortex vulnerable to seizures.

The notion that glutamate and GABA dysregulation leads to excitotoxicity is not a new concept [46]. Excitotoxicity initiates a metabolic cascade following both mild and severe TBI that may ultimately contribute to the neurologic sequelae that follow injury [4,47]. Depending on the severity of injury a patient may recover fully, or be left with impairments ranging from subtle neurocognitive difficulties to post-traumatic epilepsy. Glutamate and GABA are central to this pathophysiology and the complicated dynamics of transmitter release, receptors and neurophysiology that follow TBI are addressed here.

## Acute Consequences of TBI

### Glutamate and GABA Changes

Following focal traumatic brain injury, such as a focal contusion or penetrating injury there is direct tissue damage at the site of injury that may cause local swelling, ischemia and or hemorrhage. The area of focal injury may be irreversibly damaged and the lesion expands as excitotoxic injury spreads through surrounding tissue, analogous to the penumbra following ischemia. Following many mechanisms of TBI, including concussion, there is a more diffuse

injury that impacts widespread areas of the brain, including axonal injury. At a molecular level there is membrane swelling and potentially rupture, neurotransmitter and ion release into the extracellular space, and  $\text{Na}^+/\text{K}^+$  pump failure. With indiscriminate glutamate release there is rising intracellular  $\text{Ca}^{++}$  that perpetuates neuronal injury [48,49].

Microdialysis studies in both humans [12,48,50] and rodents [14] demonstrate an immediate rise in extracellular glutamate following severe TBI. In humans, Chamoun and colleagues demonstrated that this rise in extracellular glutamate, recorded from 24 hours after injury, lasts for as long as four days, and is directly proportional to posttraumatic mortality [12]. In a rodent model, using controlled cortical impact (CCI), microdialysis studies have demonstrated increased extracellular glutamate at 1 hour after injury [14], although the initial peak with fluid percussion injury (FPI) is much more acute [51].

In contrast to these microdialysis studies, magnetic resonance spectroscopy (MRS) studies demonstrate a decrease in glutamate at 2 and 4 hours after a CCI model with an open skull injury [52]. Additionally, over the same time period there is an increase in “pericontusional” glutamine. Similarly, in a moderate-severe TBI model using CCI that leads to a brain contusion, there was a decrease in glutamate as measured by MRS from days 0–14. There was a corresponding transient increase in glutamine in lesional cortex on days 0 and 1. In deeper, perilesional tissue of the hippocampus, the greatest increase in glutamine was on day 3, while glutamate remained decreased to a lesser extent over the course of the 2 week observation [53]. Although, there are likely differences in pathophysiology between mild TBI in humans and these severe TBI animal models, there is a similar pattern of MRS changes. Following concussion in humans there was a decrease in glutamate 1 – 6 days in motor cortex, but not dorsal lateral prefrontal cortex (DLPFC) or hippocampi. Glutamate returned to baseline in the chronic phase of injury at 6 months [54]. The authors conclude that this change was related to the motor cortex’s vulnerability to injury, although it remains unclear why this should occur in the motor cortex but not DLPFC.

To summarize, microdialysis studies demonstrate an increase in synaptic glutamate following TBI, while MRS exhibits a decrease in total glutamate and increase in glutamine. The differences between microdialysis and MRS findings may be related to injury severity [55] and models, but also highlights two points of distinction: 1. Microdialysis is capable of testing solely extracellular glutamate, while MRS tests both intra and extracellular glutamate. 2. There is a difference in the pathophysiology of lesional and perilesional cortex.

Microdialysis studies confirm the rapid release of glutamate into the extracellular space, while MRS detects glutamate in vesicles in the presynaptic cell plus glutamate in the synaptic space. Thus, the MRS-microdialysis discrepancy may be explained by glutamate depletion from presynaptic vesicles, the uptake of glutamate from the synaptic cleft by neighboring astrocytes, and rapid conversion into glutamine leading to a total decrease in glutamate as measured by MRS. This contributes to a net increase in synaptic glutamate, as demonstrated by microdialysis studies, leading to further post-synaptic excitotoxic injury. These findings may be related to the severity of injury or due to damaged compensatory mechanisms, such as the glutamate transporter, both resulting in a net increase in synaptic glutamate.

Synaptic glutamate is taken up by astrocytes expressing EAAT2/GLT-1 [19,20]. These transporters are down regulated in a number of pathologic processes, including hypoxic-ischemic injury [56], stroke [57], and Huntington's disease [58]. Specifically in severe TBI, our lab has demonstrated that GLT-1 is down-regulated 7 days after TBI in a rat lateral fluid percussion model. These rats reliably develop post-traumatic seizures at 12 weeks after injury. Seven days of treatment with ceftriaxone, a common beta-lactam antibiotic, restores GLT-1 expression to normal levels and reduces post-traumatic epilepsy [13]. The mechanism by which ceftriaxone restores GLT-1 protein levels is unclear, however ceftriaxone has demonstrated neuroprotective capacity in a range of CNS models [59]. The decrease in GLT-1 does not appear to persist when measured 2–4 weeks after injury [60].

Harris and colleagues highlight a difference in the temporal course of glutamate release and reuptake between lesional and perilesional tissue. In “pericontusional” hippocampus, glutamine did not peak until day 3 implying a slower, ongoing glutamate release that may indicate that tissue remains viable beyond the initial injury. They also demonstrated a decrease in GABA on day 1 in lesional, but not deeper hippocampal tissue, which they propose is due to decreased conversion of glutamate to GABA [53]. Therefore, ongoing excitatory and inhibitory imbalance may not be related to abnormalities in the amount of glutamate in the synaptic space or its reuptake. Instead, changes in receptors or cell populations may be responsible (see Figure, Panel B).

### Acute Receptor Changes

Following CCI, NMDAR show significant acute downregulation subunits NR1, NR2A and NR2B that return to baseline levels after 24 hours [61]. In rodents following FPI total NR2B protein and phosphorylation are down-regulated leading to destabilization of the NMDA receptor [62]. In addition to cumulative receptor downregulation, lateral FPI leads to a decrease in NR2A and increase in NR2B subunits in cortical NMDAR. In the postnatal day 19 rat pup, lateral FPI elicits a similar NR2A to NR2B shift, in both cortex and particularly in hippocampus [63]. The timing of this subunit shift in hippocampal NMDARs occurs predominantly within the first post-injury week, and corresponds to the time window of diminished experience-dependent plasticity normally induced by rearing in an enriched environment (EE). Rat pups reared in EE during the first post-injury week show impaired cortical thickening [64], altered dendritic arborization [65] and a failure of EE-induced enhancements in spatial learning and memory [66]. Additionally, following lateral FPI in rats, NMDA receptor blockade blocks immediate early gene (IEG) activation in the hippocampus 24 hours after injury. Specifically, elevations in brain-derived neurotrophic factor (BDNF) and *Bax*, a marker of apoptosis are decreased [67].

AMPA expression and function is also impacted by TBI and may lead to excitotoxic injury. In the acute phase GluR1 receptors are upregulated following TBI, leading to increased calcium entry and subsequent nondiscriminate activation of all calcium/calmodulin-dependent protein kinases (CaMKs). The selective activation of these CaMKs is important for normal memory function, therefore the lack of specific activation patterns leads to impaired function even in the absence of cell death [68]. Following an *in vitro* and *in vivo* TBI model there is decreased GluR2 subunit expression, which is NMDAR mediated



[69]. Reduced GluR2 allows for increased intracellular  $\text{Ca}^{++}$  flux [37]. Increased intracellular  $\text{Ca}^{++}$  flux through AMPARs, and via the relatively increased numbers of NR2B-containing NMDARs, lead to greater post-TBI vulnerability and likely increased neuronal death.

Blocking GABA-A receptors acutely induces seizures in rats following lateral FPI and leads to more pronounced structural damage, which underscores the critical contribution of GABA signaling to neuronal health in acute injury [70]. There are also differences in GABA-A subunit expression that occur acutely that vary by animal and TBI model, however subunits responsible for the phasic inhibition ( $\alpha 1/\gamma 2$ ) are generally down-regulated following TBI, while those responsible for the tonic inhibition ( $\alpha 4/\delta 1$ ) are up-regulated. Raible and colleagues found a decrease in the  $\alpha 1$  subunit at 24 and 48 hours that persisted for at least one week in rats injured by FPI, while there was an increase in the  $\alpha 4$  subunit at 24 hours, but not 1 week. The authors point to previous evidence of a similar pattern of subunit expression that plays a role in the hyperexcitability of hippocampus in models of status epilepticus [71].

These changes in GABA-A subunit expression appear closely related to the glutamate induced excitatory signal. GABA  $\alpha 1$  and  $\gamma 2$  subunit expression are increased in the hours after diffuse FPI in rats, but decreased by 24 hours. Changes in expression can be blocked by MK-801, an NMDA receptor blocker that prevents  $\text{Ca}^{++}$  influx into the post-synaptic cell following TBI and glutamate release. The authors suggest that  $\text{Ca}^{++}$  blockade may prevent the  $\alpha 1$  subunit mediated role in post-TBI apoptosis [72] (see Table).

## Subacute Consequences of TBI

### Glutamate and GABA Changes

The window of post-traumatic epileptogenesis, as well as the post-TBI window of vulnerability to a second injury, extends beyond the acute period. The pathophysiology that follows in the days, weeks and months after injury involve compensatory processes of receptor up and down regulation, alterations in subunit composition and a growing imbalance of glutamate driven excitation and GABA mediated inhibition. A recent study by Cantu and colleagues highlights the early phases of this imbalance in glutamate and GABA and points to mechanisms that may lead to post-traumatic epilepsy. In slice preparations, using a glutamate biosensor 2–4 weeks following controlled cortical impact they demonstrated extracellular glutamate signaling was increased in cortical networks. The highest glutamate signal occurs in perilesional tissue adjacent to the direct injury. Additionally, at the onset of a seizure the glutamate biosensor signal spreads from medial to lateral and proximal to distal away from the site of direct injury [60]. The mechanism of these changes may be related to changes in cell populations, particularly loss of parvalbumin positive GABA interneurons [45,60,73,74] and/or differences in receptor populations for glutamate and GABA.

### Subacute Receptor Changes

Two to four weeks following CCI, in slice preparations, NMDA, but not AMPA, receptor blockade prevents epileptiform activity [60]. Further NMDAR investigation in the subacute

time-frame has found changes that may underlie a form of maladaptive neuroplasticity. Reger and colleagues, using a lateral FPI in rats demonstrated an increase in the NR1 subunit of the NMDAR in the ipsilateral basolateral amygdala 2 weeks after injury. In this setting the animals had enhanced but perhaps maladaptive fear learning related to context and discrete cues. This may represent a potential molecular underpinning of the post-traumatic stress disorder associated with TBI and may be seen in patients with more mild injuries [75–77].

There is also ongoing GABA-A receptor changes. Kharlamov and colleagues found a reduction in the  $\gamma 2$  subunit (phasic inhibition) and an increase in the  $\delta 1$  subunit (tonic inhibition) in rats at 7 days that developed seizures following CCI [43]. These changes in GABA-A subunit expression further tip the balance towards excitation over inhibition.

## Chronic Consequences of TBI

### Glutamate and GABA Changes

In the chronic stages of injury following TBI there are accumulation of cellular injuries and compensatory changes that result in an imbalance of excitation and inhibition, leading to post-traumatic seizures or neurocognitive and behavioral changes. Recently, there is a growing number of studies in TBI that have employed transcranial magnetic stimulation (TMS) as a means to assess the balance of glutamate mediated excitation and GABA mediated inhibition [78,79]. TMS is a method for focal cortical stimulation where small intracranial electrical currents are induced by a strong and fluctuating extracranial magnetic field [80,81]. One method of testing couples motor cortex stimulation by TMS with surface EMG recordings in the contralateral limb that results in a motor evoked potential (MEP). From the MEP, the degree of corticospinal excitability mediated by glutamate, and intracortical inhibition mediated at least in part by GABA-B receptors, can be measured [82]. In common TMS terminology, measures of short interval intracortical inhibition (SICI), intracortical facilitation (ICF), or long-interval intracortical inhibition (LICI) can be assessed based on timing, frequency and amplitude of stimulation and EMG recordings. Abnormalities in these measures are indicative of imbalance between GABA mediated inhibition and glutamate mediated excitation or facilitation (excitatory: inhibitory, E:I ratio).

TMS studies in mild TBI have identified chronic changes in glutamate-GABA balance. Théoret's group has demonstrated an increase in GABA-B mediated inhibition in asymptomatic athletes with at least two concussions at greater than 9 months after injury. The authors conclude that GABA up-regulation may be a long-term compensatory mechanism against glutamate excitotoxicity [82]. More recently, the same lab looked for abnormalities in the MRS spectra of GABA, glutamate and glutamine, as well as TMS determined inhibition patterns of the motor cortex, occurring 3 years after 1–4 concussions. They found no differences in metabolism, cortical thickness, cortical connectivity, and contrary to previous studies no significant difference in GABA-B mediated inhibition. This difference with their prior study may be attributed to the longer time elapsed since concussion and the fewer number of concussions in the latter group. They did, however, find alterations in the balance of excitation and inhibition in concussed athletes based on the lack of correlation between GABA and glutamate measured by MRS [83].

More severe TBI models that lead to post-traumatic epilepsy months to years following injury have received ongoing investigation in our labs and others. It has been appreciated for some time that neuronal circuits are modulated by inhibitory GABAergic neurons and that these neurons may be damaged by TBI [74,84]. More recently, Pavlov and colleagues found a progressive loss of phasic inhibition with corresponding loss of parvalbumin positive GABA interneurons (see Figure, Panel C). They observed this in the ipsilateral hippocampus at 1 month following a lateral fluid percussion injury, and by 6 months in the contralateral hemisphere. They did not see a significant change in subunit expression or deficits in tonic inhibition [85]. Loss of parvalbumin positive GABA interneurons following TBI [60,86,87] leads to deficits in gamma oscillations that are important for modulating excitatory signals [45]. In addition to loss of GABAergic interneurons and inhibitory synapses there are also increased and abnormal excitatory synapses impacting neuronal connectivity [88].

Finally, deficits in the synthesis of neurotransmitters may play a role in tipping the balance of excitation and inhibition. GABA is synthesized by glutamic acid decarboxylase; therefore, a decrease in this enzyme could lead to decreased inhibition. Recently, genetic variability in humans in GAD gene expression was shown to increase the risk of PTE [89]. In an animal study, GAD-67 has been shown to be decreased following lateral FPI [75]. Conversely, GAD-67 was initially increased 1 month after a moderate to severe controlled cortical impact, however this did not persist to 4 months despite ongoing deficits in working memory [90].

### Chronic Receptor Changes

An increase in the NR2B-containing NMDAR leads to persistent  $Ca^{++}$  influx that stretches from the acute to chronic phases following injury [91]. In the chronic setting, rats that developed post-traumatic epilepsy up to 5 months following CCI had an increase in NR2B subunit compared with both rats who did not develop seizures after injury and controls [43]. Similarly, there is evidence of long lasting AMPAR changes. In a more severe TBI rodent model leading to PTE, GluR1 was downregulated several months after CCI, related to possibly altered phosphorylation or a compensatory mechanism [43].

### Implications for Neuroprotection

TBI pathophysiology likely differs between lesional and perilesional tissue and severe and mild injury. Cell injury proceeds more slowly in the brain tissue that is immediately proximal to the most severe injury and may be reversible in this penumbra. Similarly, following concussion the majority of brain injury is reversible given the typical course of symptom resolution [92–95]. Therefore the pathophysiology of mild TBI likely has similarities with more mildly affected perilesional tissue in severe TBI models. In these brain areas with reversible damage the opportunity to decrease acute glutamate excitotoxicity holds promise for neuroprotection. For example, NMDA receptor blockade decreases epileptiform discharges [60], excitatory synaptic strength [67], and apoptosis [67,72]. Removing glutamate from the synapse using scavengers, such as pyruvate and oxaloacetate an hour after weight-drop TBI, leads to an increase in surviving hippocampal neurons 30 days after injury [96]. There is also evidence that by removing glutamate from the synapse more efficiently through up-regulation of glutamate transporters, either by

ceftriaxone [13] or with the steroid dehydroepiandrosterone [97], there is a decrease in post-traumatic seizures.

Techniques in neuromodulation also hold promise for treatment following TBI. A recent study using anodal transcranial direct current stimulation (tDCS) combined with MRS demonstrated a reduction in GABA, but not glutamate or glutamine concentrations, in the motor cortex and improved motor memory [98]. Although this was not a study on TBI patients, the ability to directly impact concentrations of neurotransmitters, as well as the ratios of excitation to inhibition with tDCS and TMS, holds promise for the treatment of TBI.

## Summary

Following traumatic brain injury immediate glutamate release sets off a cascade of metabolic changes, which includes both the expanding lesion itself and the brain's attempt to compensate (summarized in Figure). Glutamate is released into the extracellular space and acts on AMPA and NMDA receptors prompting  $\text{Ca}^{++}$  ions to flow into the post-synaptic neuron. Glutamate is then taken up into astrocytes by the glutamate transporter. TBI-induced decreases in this transporter allow excess glutamate to remain in the synapse and continue its excitotoxic actions. In astrocytes glutamate is converted to glutamine and returned to its presynaptic cell or neighboring GABA interneuron for conversion back to glutamate and then to GABA, respectively. Acute decreases in GAD and/or a decrease in glutamine traveling to GABA interneurons may decrease GABA synthesis and impact local inhibition.

Early after TBI, in cortical and hippocampal regions, there is activation of extrasynaptic NR2B-containing NMDARs and downregulation of NR2A, resulting in persistent  $\text{Ca}^{++}$  flux, impaired neuroplasticity and an increased risk for neuronal cell death. Downregulation of the GluR2 AMPAR subunit renders these receptors calcium-permeable and may exacerbate injury. Later, NMDAR subunits may recover, with concomitant improvements in neural activation, increased expression of neurotrophins and enhanced plasticity. This delayed re-activation of circuitry may be mediated not only by changes in NMDARs but also AMPARs. However, with the restoration of neural activation comes the risk of maladaptive excitatory neurotransmission, including enhanced fear/anxiety as well as the development of post-traumatic seizures.

In the subsequent phase of excitotoxic injury there are changes in receptor composition that are likely a combination of direct injury, as well as compensatory changes that are meant to combat the excessive excitatory input. GABA interneurons act to synchronize and time neuronal signals across large networks, and dysfunction in particular GABA receptor subunits leads to abnormal patterns of phasic and tonic inhibition thus making the local environment hyperexcitable and at risk for seizures. Additionally, through normal patterns of inhibition, GABA-A receptors mediate gamma oscillations that play a role in higher cognitive functions. These gamma oscillations appear to rely on fast-spiking parvalbumin positive GABA interneurons, which are uniquely susceptible to loss following TBI. Therefore, investigations into the mechanism of this cell loss are a key area to target to improve neurocognitive outcomes and post-traumatic epilepsy.

## Conclusion

Following experimental TBI, there are dynamic changes in excitatory-inhibitory balance that result in neuronal dysfunction and may result in long-term sequelae. This imbalance is a result of increased glutamate release, faulty reuptake, and changes in the population of receptors and inhibitory interneurons. Given the complexity of the pathophysiology and the heterogeneity of injuries it is crucial to continue building our understanding of this imbalance with the goal of finding therapeutic and neuroprotective targets.

## Acknowledgments

**Support:** CCG is supported by the Joseph Drown Foundation, NIH, NCAA, Dept of Defense, Today's and Tomorrow's Children Fund, UCLA Brain Injury Research Center and the UCLA Steve Tisch BrainSPORT Program. AR is supported by NIH, Dept of Defense, CURE, and the Harvard Translational Research Program.

## References

Papers of particular interest, published recently have been highlighted as follows:

- Of importance
  - Of major importance
1. Spruston N. Pyramidal neurons: dendritic structure and synaptic integration. *Nature Reviews Neuroscience*. 2008 Mar; 9(3):206–21. [PubMed: 18270515]
  2. Kandel, E. *Principles of Neural Science*. 5. Kandel, ER.; Schwartz, JH.; Jessell, TM.; Siegelbaum, SA.; Hudspeth, AJ., editors. McGraw Hill Professional; 2013. p. 210-306.
  3. Castro-Alamancos MA, Connors BW. Thalamocortical synapses. *Progress in Neurobiology*. 1997 Apr; 51(6):581–606. [PubMed: 9175158]
  4. Giza CC, Hovda DA. The New Neurometabolic Cascade of Concussion. *Neurosurgery*. 2014 Oct. 75:S24–S33. [PubMed: 25232881]
  5. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. *Cellular and Molecular Life Sciences (CMLS)*. 2004 Mar 1; 61(6):657–68. [PubMed: 15052409]
  6. Lowenstein DH. Epilepsy after head injury: An overview. *Epilepsia*. 2009 Feb. 50:4–9. [PubMed: 19187288]
  7. Weiss GH, MSA, Vance SC, Grafman JH, Jabbari B. Predicting Posttraumatic Epilepsy in Penetrating Head Injury. *Arch Neurol American Medical Association*. 1986 Aug 1; 43(8):771–3.
  8. Salazar A, Jabbari B, Vance SC, Grafman J, Amin D, Dillon JD. Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. *Neurology*. 1985;1406–14. [PubMed: 3929158]
  9. Annegers JF, Rocca WA, Hauser WA. Causes of Epilepsy: Contributions of the Rochester Epidemiology Project. *Mayo Clinic Proceedings*. 1996 Jun; 71(6):570–5. [PubMed: 8642886]
  10. Pitkänen A, Kharatishvili I, Karhunen H, Lukasiuk K, Immonen R, Nairismägi J, et al. Epileptogenesis in Experimental Models. *Epilepsia*. 2007 Apr; 48(s2):13–20. [PubMed: 17571349]
  11. Castile L, Collins CL, McIlvain NM, Comstock RD. The epidemiology of new versus recurrent sports concussions among high school athletes, 2005–2010. Castile L, Collins CL, McIlvain NM, Comstock RD. *British Journal of Sports Medicine*. 2012; 46(8):603–610. [PubMed: 22144000]
  12. Chamoun R, Suki D, Gopinath SP, Goodman JC, Robertson C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. *J Neurosurg*. 2010 Sep; 113(3):564–70. [PubMed: 20113156]

- 13•• Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. Ceftriaxone Treatment after Traumatic Brain Injury Restores Expression of the Glutamate Transporter, GLT-1, Reduces Regional Gliosis, and Reduces Post-Traumatic Seizures in the Rat. *Journal of Neurotrauma*. 2013 Aug 15; 30(16):1434–41. This work highlights a potential neuroprotective mechanism by restoring the glutamate transporter with ceftriaxone. [PubMed: 23510201]
14. Folkersma H, Dingley JCF, van Berckel BN, Rozemuller A, Boellaard R, Huisman MC, et al. Increased cerebral (R)-[11C]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: a longitudinal pilot study. *Journal of Neuroinflammation BioMed Central Ltd*. 2011 Jun 14;8(1):67.
15. Goforth PB, Ren J, Schwartz BS, Satin LS. Excitatory synaptic transmission and network activity are depressed following mechanical injury in cortical neurons. *J Neurophysiol*. 2011 May; 105(5): 2350–63. [PubMed: 21346214]
16. Luo P, Fei F, Zhang L, Qu Y, Fei Z. The role of glutamate receptors in traumatic brain injury: Implications for postsynaptic density in pathophysiology. *Brain Research Bulletin*. 2011 Jul; 85(6):313–20. [PubMed: 21605633]
17. Krebs AH. Metabolism of Amiono-Acids: The synthesis of glutamine from glutamic acid and ammonia, and the enzymatic hydrolysis of glutamine in animal tissues. *Biochemical Journal*. 1953 Jun 29; 29(8):1951–69. [PubMed: 16745865]
18. Neher E, Sakaba T. Multiple Roles of Calcium Ions in the Regulation of Neurotransmitter Release. *Neuron*. 2008 Sep 25; 59(6):861–72. [PubMed: 18817727]
19. Furness DN, Dehnes Y, Akhtar AQ, Rossi DJ, Hamann M, Grutle NJ, et al. A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: New insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2). *Neuroscience*. 2008 Nov; 157(1):80–94. [PubMed: 18805467]
20. Melone M, Bellesi M, Conti F. Synaptic localization of GLT-1a in the rat somatic sensory cortex. *Glia*. 2009 Jan 1; 57(1):108–17. [PubMed: 18720407]
21. Walls AB, Waagepetersen HS, Bak LK, Schousboe A, Sonnewald U. The Glutamine-Glutamate/GABA Cycle: Function, Regional Differences in Glutamate and GABA Production and Effects of Interference with GABA Metabolism. *Neurochem Res*. 2014 Nov 8.
22. Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. *J Physiol (Lond)*. 1983 Jan. 334:33–46. [PubMed: 6306230]
23. Paula-Lima AC, Brito-Moreira J, Ferreira ST. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. *Journal of Neurochemistry*. 2013 May 28; 126(2):191–202. [PubMed: 23668663]
24. Featherstone RE, Shin R, Kogan JH, Liang Y, Matsumoto M, Siegel SJ. Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: Implications for schizophrenia prodromal population. *Neurobiology of Disease Elsevier B.V*. 2015 Jan 1; 73(C):289–95.
25. Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. *Nature*. 2005 Nov 10; 438(7065):185–92. [PubMed: 16281028]
26. Chen Q, He S, Hu XL, Yu J, Zhou Y, Zheng J, et al. Differential Roles of NR2A- and NR2B-Containing NMDA Receptors in Activity-Dependent Brain-Derived Neurotrophic Factor Gene Regulation and Limbic Epileptogenesis. *J Neurosci*. 2007 Jan 17; 27(3):542–52. [PubMed: 17234586]
27. Zhou X, Moon C, Zheng F, Luo Y, Soellner D, Nuñez JL, et al. N-methyl-D-aspartate-stimulated ERK1/2 signaling and the transcriptional up-regulation of plasticity-related genes are developmentally regulated following in vitro neuronal maturation. *J Neurosci Res*. 2009 Sep; 87(12):2632–44. [PubMed: 19396876]
28. Choo AM, Geddes-Klein DM, Hockenberry A, Scarsella D, Mesfin MN, Singh P, et al. NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult. *Neurochemistry International Elsevier Ltd*. 2012 Apr 1; 60(5):506–16.


29. Li B, Chen N, Luo T, Otsu Y, Murphy TH, Raymond LA. Differential regulation of synaptic and extra-synaptic NMDA receptors. *Nat Neurosci*. 2002 Aug 26; 5(9):833–4. [PubMed: 12195433]
30. Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. *Trends in Neurosciences*. 2003 Feb; 26(2):81–9. [PubMed: 12536131]
31. Patel TP, Ventre SC, Geddes-Klein D, Singh PK, Meaney DF. Single-Neuron NMDA Receptor Phenotype Influences Neuronal Rewiring and Reintegration following Traumatic Injury. *J Neurosci*. 2014 Mar 19; 34(12):4200–13. This elegant study begins to examine the underlying mechanism for changes in connectivity following TBI. [PubMed: 24647941]
32. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. *Science*. 2004 May 14; 304(5673):1021–4. [PubMed: 15143284]
33. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. *Neuron*. 1994 Mar; 12(3):529–40. [PubMed: 7512349]
34. Chater TE. The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. 2014 Nov.24:1–14.
35. Sanderson DJ, Good MA, Seeburg PH, Sprengel R, Rawlins JNP, Bannerman DM. The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory. *Progress in Brain Research*. 2008:20.
36. Wang JQ, Arora A, Yang L, Parelkar NK, Zhang G, Liu X, et al. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. *Mol Neurobiol Humana Press*. 2005 Dec; 32(3): 237–49.
37. Isaac JTR, Ashby MC, McBain CJ. The Role of the GluR2 Subunit in AMPA Receptor Function and Synaptic Plasticity. *Neuron*. 2007 Jun 21; 54(6):859–71. [PubMed: 17582328]
38. Seidenman KJ, Steinberg JP, Haganir R, Malinow R. Glutamate receptor subunit 2 Serine 880 phosphorylation modulates synaptic transmission and mediates plasticity in CA1 pyramidal cells. *J Neurosci*. 2003 Oct 8; 23(27):9220–8. [PubMed: 14534256]
39. Cooper, JR.; Bloom, FE.; Roth, RH. *The Biochemical Basis of Neuropharmacology*. 8. New York: University Press; 2002.
40. Olsen RW, Sieghart W. GABAA receptors: Subtypes provide diversity of function and pharmacology. *Neuropharmacology*. 2009 Jan 1; 56(1):141–8. [PubMed: 18760291]
41. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. *Nature Reviews Neuroscience*. 2005 Mar; 6(3):215–29. [PubMed: 15738957]
42. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. *Nature Reviews Neuroscience*. 2007 Jan; 8(1):45–56. [PubMed: 17180162]
43. Kharlamov EA, Lepsveridze E, Meparishvili M, Solomonina RO, Lu B, Miller ER, et al. Alterations of GABAA and glutamate receptor subunits and heat shock protein in rat hippocampus following traumatic brain injury and in posttraumatic epilepsy. *Epilepsy Res Elsevier BV*. 2011 Jun 1; 95(1–2):20–34.
44. Gonchar Y, Wang Q, Burkhalter A. Multiple distinct subtypes of GABAergic neurons in mouse visual cortex identified by triple immunostaining. *Front Neuroanat*. 2007; 1:3. [PubMed: 18958197]
45. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. *Nature*. 2009 May 25; 459(7247):698–702. [PubMed: 19396159]
46. Chagnac-Amitai Y, Connors BW. Horizontal spread of synchronized activity in neocortex and its control by GABA-mediated inhibition. *J Neurophysiol*. 1989 Apr; 61(4):747–58. [PubMed: 2542471]
47. Bramlett H, Dietrich WD. Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurologic Outcomes. *Journal of Neurotrauma*. 2014 Aug 26.:140826105716007.
48. Bullock R, Zauner A, Woodward JJ, Myseros J, Choi SC, Ward JD, et al. Factors affecting excitatory amino acid release following severe human head injury. *J Neurosurg*. 1998 Oct; 89(4): 507–18. [PubMed: 9761042]

49. Yokobori, S.; Bullock, MR. Pathobiology of Traumatic Brain Injury. In: Zasler, ND.; Katz, DI.; Zafonte, RD., editors. *Brain Injury Medicine*. 2. Demos Medical Publishing; 2012. p. 137-147.
50. Vespa P, Prins M, Ronne-Engstrom E, Caron M, Shalmon E, Hovda DA, et al. Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. *J Neurosurg*. 1998 Dec; 89(6):971–82. [PubMed: 9833824]
51. Katayama Y, Becker DP, Tamura T, Hovda DA. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. *J Neurosurg*. 1990 Dec; 73(6):889–900. [PubMed: 1977896]
52. Xu S, Zhuo J, Racz J, Shi D, Roys S, Fiskum G, et al. Early Microstructural and Metabolic Changes following Controlled Cortical Impact Injury in Rat: A Magnetic Resonance Imaging and Spectroscopy Study. *Journal of Neurotrauma*. 2011 Oct; 28(10):2091–102. [PubMed: 21761962]
53. Harris JL, Yeh H-W, Choi I-Y, Lee P, Berman NE, Swerdlow RH, et al. Altered neurochemical profile after traumatic brain injury. *Nature Publishing Group*. 2012 Aug 15; 32(12):2122–34.
54. Henry LC, Tremblay S, Boulanger Y, Ellemberg D, Lassonde M. Neurometabolic changes in the acute phase after sports concussions correlate with symptom severity. *Journal of Neurotrauma*. 2010 Jan; 27(1):65–76. [PubMed: 19761385]
55. Saatman KE, Duhaime A-C, Bullock R, Maas AIR, Valadka A, Manley GT. Classification of Traumatic Brain Injury for Targeted Therapies. *Journal of Neurotrauma*. 2008 Jul; 25(7):719–38. [PubMed: 18627252]
56. Lai PC, Huang YT, Wu CC, Lai C-J, Wang PJ, Chiu TH. Ceftriaxone attenuates hypoxic-ischemic brain injury in neonatal rats. *J Biomed Sci BioMed Central Ltd*. 2011 Sep 21.18(1):69.
57. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, et al. Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation. *Stroke*. 2006 Dec 22; 38(1):177–82. [PubMed: 17122424]
58. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. *Neuroscience*. 2008 Apr; 153(1):329–37. [PubMed: 18353560]
59. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. *Nature*. 2005 Jan 6; 433(7021):73–7. [PubMed: 15635412]
- 60••. Cantu D, Walker K, Andresen L, Taylor-Weiner A, Hampton D, Tesco G, et al. Traumatic Brain Injury Increases Cortical Glutamate Network Activity by Compromising GABAergic Control. *Cereb Cortex*. 2014 Mar 7. This study looks at the relationship of glutamate and GABA changes in cell physiology and populations of GABA interneurons.
61. Kumar A, Zou L, Yuan X, Long Y, Yang K. N-methyl-D-aspartate receptors: Transient loss of NR1/NR2A/NR2B subunits after traumatic brain injury in a rodent model. *J Neurosci Res*. 2002 Feb 28; 67(6):781–6. [PubMed: 11891792]
- 62•. Park Y, Luo T, Zhang F, Liu C, Bramlett HM, Dietrich WD, et al. Downregulation of Src-kinase and glutamate-receptor phosphorylation after traumatic brain injury. *J Cereb Blood Flow Metab*. 2013 Jul 10; 33(10):1642–9. This study examines potential mechanisms of NMDA receptor changes following TBI. [PubMed: 23838828]
63. Giza CC, SantaMaria NS, Hovda DA. N-Methyl-D-Aspartate Receptor Subunit Changes after Traumatic Injury to the Developing Brain. *Journal of Neurotrauma*. 2006 Jun; 23(6):950–61. [PubMed: 16774479]
64. Fineman I, Giza CC, Nahed BV, Lee SM, Hovda DA. Inhibition of neocortical plasticity during development by a moderate concussive brain injury. *Journal of Neurotrauma*. 2000 Sep; 17(9): 739–49. [PubMed: 11011814]
65. Ip EY-Y, Giza CC, Griesbach GS, Hovda DA. Effects of enriched environment and fluid percussion injury on dendritic arborization within the cerebral cortex of the developing rat. *Journal of Neurotrauma*. 2002 May; 19(5):573–85. [PubMed: 12042093]
66. Giza CC, Griesbach GS, Hovda DA. Experience-dependent behavioral plasticity is disturbed following traumatic injury to the immature brain. *Behavioural Brain Research*. 2005 Feb; 157(1): 11–22. [PubMed: 15617766]



- 67• Wang Y, Hameed MQ, Rakhade SN, Iglesias AH, Muller PA, Mou D-L, et al. Hippocampal immediate early gene transcription in the rat fluid percussion traumatic brain injury model. *NeuroReport*. 2014 Aug; 25(12):954–9. This study examines down-stream changes in immediate early genes that follow TBI and highlights the NMDA receptor as a potential mediator of these changes. [PubMed: 24978397]
68. Atkins CM, Chen S, Alonso OF, Dietrich WD, Hu B-R. Activation of calcium/calmodulin-dependent protein kinases after traumatic brain injury. *J Cereb Blood Flow Metab*. 2006 Mar 29; 26(12):1507–18. [PubMed: 16570077]
69. Bell JD, Park E, Ai J, Baker AJ. PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma. *Cell Death and Differentiation*. 2009 Jul 31; 16(12):1665–80. [PubMed: 19644508]
70. Bao Y-H, Bramlett HM, Atkins CM, Truettner JS, Lotocki G, Alonso OF, et al. Post-Traumatic Seizures Exacerbate Histopathological Damage after Fluid-Perussion Brain Injury. *Journal of Neurotrauma*. 2011 Jan; 28(1):35–42. [PubMed: 20836615]
- 71• Raible DJ, Frey LC, Cruz Del Angel Y, Russek SJ, Brooks-Kayal AR. GABA A Receptor Regulation after Experimental Traumatic Brain Injury. *Journal of Neurotrauma*. 2012 Nov; 29(16):2548–54. This study examines potential mechanisms of GABA-A receptor changes following TBI. [PubMed: 22827467]
72. Gibson CJ, Meyer RC, Hamm RJ. Traumatic brain injury and the effects of diazepam, diltiazem, and MK-801 on GABA-A receptor subunit expression in rat hippocampus. *J Biomed Sci*. 2010; 17(1):38. [PubMed: 20482789]
73. Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH. Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. *J Neurosci*. 1997 May 15; 17(10):3727–38. [PubMed: 9133393]
74. Lowenstein DH, Thomas MJ, Smith DH, McIntosh TK. Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus. *J Neurosci*. 1992 Dec; 12(12):4846–53. [PubMed: 1464770]
- 75• Reger ML, Poulos AM, Buen F, Giza CC, Hovda DA, Fanselow MS. Concussive brain injury enhances fear learning and excitatory processes in the amygdala. *Biol Psychiatry*. 2012 Feb 15; 71(4):335–43. [PubMed: 22169439]
76. Elder GA, Dorr NP, De Gasperi R, Gama Sosa MA, Shaughness MC, Maudlin-Jeronimo E, et al. Blast Exposure Induces Post-Traumatic Stress Disorder-Related Traits in a Rat Model of Mild Traumatic Brain Injury. *Journal of Neurotrauma*. 2012 Nov; 29(16):2564–75. [PubMed: 22780833]
77. Meyer DL, Davies DR, Barr JL, Manzerra P, Forster GL. Mild traumatic brain injury in the rat alters neuronal number in the limbic system and increases conditioned fear and anxiety-like behaviors. *Experimental Neurology Elsevier Inc*. 2012 Jun 1; 235(2):574–87.
78. Villamar MF, Santos Portilla A, Fregni F, Zafonte R. Noninvasive Brain Stimulation to Modulate Neuroplasticity in Traumatic Brain Injury. *Neuromodulation: Technology at the Neural Interface Blackwell Publishing Inc*. 2012 Jun 14; 15(4):326–38.
79. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Bernabeu M, Tormos JM, Pascual-Leone A. Noninvasive Brain Stimulation in Traumatic Brain Injury. *Journal of Head Trauma Rehabilitation*. 2012; 27(4):274–92. [PubMed: 21691215]
80. Hallett M. Transcranial Magnetic Stimulation: A Primer. *Neuron*. 2007 Jul; 55(2):187–99. [PubMed: 17640522]
81. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. *The Lancet Neurology*. 2003 Mar; 2(3):145–56. [PubMed: 12849236]
- 82• De Beaumont L, Tremblay S, Poirier J, Lassonde M, Théoret H. Altered bidirectional plasticity and reduced implicit motor learning in concussed athletes. *Cereb Cortex*. 2012 Jan; 22(1):112–21. [PubMed: 21572090]
83. Tremblay S, Beaulé V, Proulx S, Tremblay S, Marja ska M, Doyon J, et al. Multimodal assessment of primary motor cortex integrity following sport concussion in asymptomatic athletes. *Clinical Neurophysiology International Federation of Clinical Neurophysiology*. 2014 Jul 1; 125(7):1371–9.

84. Hicks RR, Smith DH, Lowenstein DH, Saint Marie R, McIntosh TK. Mild experimental brain injury in the rat induces cognitive deficits associated with regional neuronal loss in the hippocampus. *Journal of Neurotrauma*. 1993; 10(4):405–14. [PubMed: 8145264]
85. Pavlov I, Huusko N, Drexel M, Kirchmair E, Sperk G, Pitkänen A, et al. Progressive loss of phasic, but not tonic, GABAA receptor-mediated inhibition in dentate granule cells in a model of post-traumatic epilepsy in rats. *Neuroscience Elsevier Inc*. 2011 Oct 27; 194(C):208–19.
86. Hameed, MQ.; Hsieh, TH.; Goodrich, GS.; Morales-Quezada, JL.; Rosenberg, PA.; Rotenberg, A. Ceftriaxone Treatment After Traumatic Brain Injury Preserves GAD-1 Expression in Rat Cortex After TBI. Washington, DC: 2014.
87. Lee, HH.; Hsieh, T-H.; Hameed, MQ.; Hensch, TK.; Rotenberg, A. Loss of parvalbumin interneurons underlies impaired cortical inhibition in post-traumatic epileptogenesis. San Diego, CA: 2013.
88. Prince DA, Parada I, Scalise K, Graber K, Jin X, Shen F. Epilepsy following cortical injury: Cellular and molecular mechanisms as targets for potential prophylaxis. *Epilepsia Blackwell Publishing Ltd*. 2009 Feb; 50(s2):30–40.
89. Darrach SD, Miller MA, Ren D, Hoh NZ, Scanlon JM, Conley YP, et al. Genetic variability in glutamic acid decarboxylase genes: Associations with post-traumatic seizures after severe TBI. *Epilepsy Res Elsevier BV*. 2013 Feb 1; 103(2–3):180–94.
90. Hoskison MM, Moore AN, Hu B, Orsi S, Kobori N, Dash PK. Persistent working memory dysfunction following traumatic brain injury: Evidence for a time-dependent mechanism. *Neuroscience*. 2009 Mar 17; 159(2):483–91. [PubMed: 19167462]
91. Osteen CL, Giza CC, Hovda DA. Injury-induced alterations in N-methyl-d-aspartate receptor subunit composition contribute to prolonged 45 calcium accumulation following lateral fluid percussion. *Neuroscience*. 2004 Jan; 128(2):305–22. [PubMed: 15350643]
92. Eisenberg MA, Meehan WP, Mannix R. Duration and course of post-concussive symptoms. *Pediatrics American Academy of Pediatrics*. 2014 Jun; 133(6):999–1006.
93. Eisenberg MA, Andrea J, Meehan W, Mannix R. Time Interval Between Concussions and Symptom Duration. *Pediatrics*. 2013 Jul 1; 132(1):8–17. [PubMed: 23753087]
94. Collins M, Lovell MR, Iverson GL, Ide T, Maroon J. Examining concussion rates and return to play in high school football players wearing newer helmet technology: a three-year prospective cohort study. *Neurosurgery*. 2006 Feb; 58(2):275–86. discussion275–86. [PubMed: 16462481]
95. Guskiewicz KM, McCrea M, Marshall SW, Cantu RC, Randolph C, Barr W, et al. Cumulative effects associated with recurrent concussion in collegiate football players: the NCAA Concussion Study. *JAMA*. 2003 Nov 19; 290(19):2549–55. [PubMed: 14625331]
96. Zlotnik A, Sinelnikov I, Gruenbaum BF, Gruenbaum SE, Dubilet M, Dubilet E, et al. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. *Anesthesiology*. 2012 Jan; 116(1):73–83. [PubMed: 22129535]
97. Mishra M, Singh R, Mukherjee S, Sharma D. Dehydroepiandrosterone's antiepileptic action in FeCl<sub>3</sub>-induced epileptogenesis involves upregulation of glutamate transporters. *Epilepsy Res*. 2013 Sep; 106(1–2):83–91. [PubMed: 23891458]
98. Kim S, Stephenson MC, Morris PG, Jackson SR. tDCS-induced alterations in GABA concentration within primary motor cortex predict motor learning and motor memory: a 7 T magnetic resonance spectroscopy study. *NeuroImage*. 2014 Oct 1.99:237–43. This study, although not on TBI patients, highlights the ability to directly impact concentrations of neurotransmitters with tDCS and TMS. [PubMed: 24904994]



**Figure. Summary of Glutamate and GABA homeostasis and changes following traumatic brain injury**

The figure illustrates a schematic relationship of a glutamatergic synapse between pyramidal neurons (green neurons), an astrocyte (bottom right), and an inhibitory GABAergic synapse between an interneuron (blue neuron in the top right) and, in this case the cell body of the pyramidal cell. **Panel A.** Baseline homeostatic relationship of glutamate and GABA begins with (1) a depolarizing current traveling down a pyramidal cell. (2) This is followed by  $\text{Ca}^{++}$  mediated release of glutamate from the presynaptic neuron and action on local AMPA and NMDA receptors. (3)  $\text{Na}^+$  enters the cell triggering depolarization, (4) followed by  $\text{Ca}^{++}$  via NMDA receptors. (5) There is subsequently immediate early gene (IEG) activation. (6) Glutamate is taken up by the GLT-1/EAAT transporter on nearby astrocytes. (7) Glutamate is converted to glutamine by glutamine synthase (GS) and shuttled back to the presynaptic cell and nearby interneurons for conversion to GABA via glutaminase (GLS) and then glutamate decarboxylase (GAD). (8) GABA is released from local interneurons and acts on GABA-A and GABA-B receptors and is taken back up by GAT-1. (9)  $\text{Cl}^-$  and  $\text{K}^+$  enter the presynaptic pyramidal cell restoring the cell membrane to its resting state. **Panel B.** Acutely following TBI there is (1) rapid depolarization of the pyramidal cell and increased  $\text{Ca}^{++}$  entry into the presynaptic cell prompting (2) increased glutamate release into the synaptic cleft. Glutamate then acts on AMPA and NMDA receptors, as there are local changes that attempt to compensate for the increased glutamate, e.g. downregulation of NMDA subunits. (3)  $\text{Na}^+$  enters the cell triggering depolarization, (4) followed by increased  $\text{Ca}^{++}$  via NMDA receptors and (5) increased IEG activation. (6) Less glutamate is removed from the synapse given decreased expression of GLT-1/EAAT transporter on astrocytes. (7) Glutamate that is taken up is rapidly converted to glutamine and recycled. (8) GABA is released from local interneurons, however (9) changes in GABA-A subunit expression lead to changes in the phasic inhibition of the presynaptic pyramidal cell and deficits in membrane repolarization. **Panel C.** Chronically following TBI there is (1) depolarization of the pyramidal cell and (2) glutamate release into the synaptic cleft, which acts on AMPA and NMDA receptors, now with different expression of receptor subunits, e.g. NR2A shifts to NR2B. (3)  $\text{Na}^+$  enters the cell triggering depolarization, (4) followed by  $\text{Ca}^{++}$  via NMDA receptors and (5) IEG activation. (6) Glutamate is taken up by the GLT-1/EAAT transporter on nearby astrocytes and (7) converted to glutamine. (8) There is GABA interneuron cell death and (9) persistent GABA-A receptor dysfunction that leads to (10) less hyperpolarization and a hyperexcitable state of the presynaptic cell. Abbreviations: Glu = glutamate, gln = glycine,  $\text{Cl}^-$  = chloride,  $\text{K}^+$  = potassium,  $\text{Na}^+$  = sodium,  $\text{Ca}^{++}$  = calcium, IEG = immediate early gene, NR2B = NMDA receptor subunit 2B, GLT/EAAT = glutamate transporter, excitatory amino acid

transporter, GS = glutamine synthase, GLS = glutaminase, GAD = glutamate decarboxylase.  
GAT-1 = GABA transporter.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1**  
**NMDA, AMPA and GABA receptors and subunits relevant in TBI**

Representation of receptor subtypes, commonly accepted localization and function, and general consequences following TBI based on the available literature.  $\text{Ca}^{++}$  influx into the postsynaptic cell leads to mitochondrial dysfunction and increased caspases and CaMK activation. The extent of these receptor and subunit changes likely differs by injury severity and brain region, which is not represented here. Abbreviations: LTD = long-term depression. LTP = long-term potentiation.

Receptor	Subtype	Localization	Function	Expression and/or Function after TBI
NMDA [25–33]	NR1	Synaptic	Enables receptor deactivation via glycine binding and particular localization with NR2 may lead to glycine-dependent desensitization	Acute: decreased Chronic: increased
	NR2A	Synaptic	Enhances excitatory synaptic strength through colocalization with NR1 and protects NR2B-mediated $\text{Ca}^{++}$ influx; NR2A-containing NMDARs respond to high-frequency stimulation to initiate LTP	Acute: decreased Chronic: decreased
	NR2B	Predominantly Extrasynaptic	Enables prolonged $\text{Ca}^{++}$ influx; NR2B-containing NMDARs respond to low-frequency stimulation to initiate LTD	Acute: decreased Chronic: increased
AMPA [2,34–38,69]	GluR1	Synaptic	Enables $\text{Na}^+$ and $\text{Ca}^{++}$ permeability; phosphorylated and upregulated in LTP	Acute: increased Chronic: decreased
	GluR2	Synaptic	Limits $\text{Ca}^{++}$ permeability	Acute: decreased Chronic: ???
GABA-A [2,29–43]	$\alpha 1/\gamma 2$	Synaptic	Enables phasic inhibition; Responds to higher and quicker GABA concentration changes	Acute & chronic: decreased
	$\alpha 4/\delta 1$	Extrasynaptic	Enables tonic inhibition; responds to lower and slower GABA concentration change	Acute & chronic: increased
GABA-B [2,21,39,82]		Extrasynaptic & Presynaptic	Hyperpolarizes membrane via opening of $\text{K}^+$ channels	Acute & chronic: increased